Phase I, Open Label First in Human Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of JFI447 [68Ga]Ga-DFC413, and Compare to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07630961

Title field or adapter rule

{'original_value': 'Phase I, Open Label First in Human Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of JFI447 [68Ga]Ga-DFC413, and Compare to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.939714+00:00

Published At

2026-08-27T00:00:00+00:00

Record Updated At

2026-08-27

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)", "Non-small Cell Lung Cancer (NSCLC)", "HR+/HER2- Ductal Breast Cancer (BC)", "HR+/HER2- Lobular Breast Cancer (BC)", "Triple Negative Breast Cancer (TNBC)", "Colorectal Cancer (CRC)", "Soft Tissue Sarcoma (STS)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-08-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07630961"

protocolSection.identificationModule.officialTitle

"Phase I, Open Label First in Human Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of JFI447 [68Ga]Ga-DFC413, and Compare to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)
• Non-small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
• HR+/HER2- Ductal Breast Cancer (BC) (protocolSection.conditionsModule.conditions)
• HR+/HER2- Lobular Breast Cancer (BC) (protocolSection.conditionsModule.conditions)
• Triple Negative Breast Cancer (TNBC) (protocolSection.conditionsModule.conditions)
• Colorectal Cancer (CRC) (protocolSection.conditionsModule.conditions)
• Soft Tissue Sarcoma (STS) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Part 1: Imaging Characterization', 'Part 2: Comparative Assessment'], 'description': 'Radioimaging agent', 'name': '68Ga-DFC413', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 2: Comparative Assessment'], 'description': 'Radioimaging agent', 'name': '68Ga-NNS309', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• 68Ga-DFC413 (protocolSection.armsInterventionsModule.interventions[].name)
• 68Ga-NNS309 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.